Other: Questionnaire
( DrugBank: - / KEGG DRUG: - )
4 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 85 | Idiopathic interstitial pneumonia | 1 |
| 93 | Primary biliary cholangitis | 1 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 94 | Primary sclerosing cholangitis | 1 |
| 106 | Cryopyrin-associated periodic syndrome | 1 |
85. Idiopathic interstitial pneumonia
Clinical trials : 768 / Drugs : 558 - (DrugBank : 126) / Drug target genes : 103 - Drug target pathways : 214
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
93. Primary biliary cholangitis
Clinical trials : 371 / Drugs : 286 - (DrugBank : 56) / Drug target genes : 35 - Drug target pathways : 105
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
94. Primary sclerosing cholangitis
Clinical trials : 189 / Drugs : 159 - (DrugBank : 46) / Drug target genes : 22 - Drug target pathways : 148
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
106. Cryopyrin-associated periodic syndrome
Clinical trials : 57 / Drugs : 38 - (DrugBank : 5) / Drug target genes : 4 - Drug target pathways : 47
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|